Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | TOP1 | P11387 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL362378 | 0.95 | TDP1 (0.69) | MAPK14TDP1ALDH1A1MAPTMAPK1 | |
| SCHEMBL360913 | 0.95 | TDP1 (0.69) | MAPK14TDP1ALDH1A1MAPTMAPK1 | |
| SCHEMBL13020043 | 0.94 | TDP1 (0.67) | MAPK14TDP1ALDH1A1MAPTMAPK1 | |
| SCHEMBL362270 | 0.87 | L3MBTL1 (0.66) | MAPK14TDP1ALDH1A1MAPTMAPK1 | |
| SCHEMBL29516689 | 0.83 | MAPK14 (0.63) | MAPK14TDP1ALDH1A1MAPK1HTT | |
| SCHEMBL284971 | 0.83 | MAPK14 (0.63) | MAPK14TDP1ALDH1A1MAPK1HTT | |
| SCHEMBL30079671 | 0.82 | MAPK14 (0.88) | MAPK14BCHEACHEADORA2ATOP1 | |
| SCHEMBL14416946 | 0.82 | MAPK14 (0.62) | MAPK14TDP1ALDH1A1MAPTMAPK1 | |
| SCHEMBL284334 | 0.82 | MAPK14 (0.88) | MAPK14BCHEACHEADORA2ATOP1 | |
| Bromide SCHEMBL28426843 | 0.81 | MAPK14 (0.61) | MAPK14TDP1ALDH1A1MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593452-B1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| EP-2802584-B1 | SALTS OF AN IP RECEPTOR AGONIST | NOVARTIS AG (CH) | 2015-11-18 | — | — | EP | disclosed |
| US-9174985-B2 | Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists | NOVARTIS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9132127-B2 | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists | NOVARTIS AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-9115129-B2 | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists | NOVARTIS AG (CH) | 2015-08-25 | — | — | US | disclosed |
| US-20150011555-A1 | Salts of an IP Receptor Agonist | NOVARTIS AG (CH) | 2015-01-08 | — | — | US | disclosed |
| US-20150005311-A1 | IP receptor agonist heterocyclic compounds | NOVARTIS AG (CH) | 2015-01-01 | — | — | US | disclosed |
| US-20140357642-A1 | IP receptor agonist heterocyclic compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| EP-2802584-A1 | SALTS OF AN IP RECEPTOR AGONIST | Novartis AG (CH) | 2014-11-19 | — | — | EP | disclosed |
| EP-2802585-A1 | FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PAH AND RELATED DISORDERS | Novartis AG (CH) | 2014-11-19 | — | — | EP | disclosed |
| EP-2802583-A1 | FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS | Novartis AG (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-8754085-B2 | Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist | NOVARTIS AG (CH) | 2014-06-17 | — | — | US | disclosed |
| WO-2013105063-A1 | FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS | NOVARTIS AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013105066-A1 | SALTS OF AN IP RECEPTOR AGONIST | NOVARTIS AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013105065-A1 | FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PAH AND RELATED DISORDERS | NOVARTIS AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| EP-2593452-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| WO-2012007539-A9 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012007539-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005311-A1 | IP receptor agonist heterocyclic compounds | PTGIR, GPR68, ACVR1 | MAPK14 1149/4885TDP1 4684/4885ALDH1A1 3004/4885 |
| US-20140357642-A1 | IP receptor agonist heterocyclic compounds | PTGIR, GPR68, GPR84 | MAPK14 1188/4885TDP1 4587/4885ALDH1A1 3232/4885 |
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | PTGIR, ACVR1, PTGFR | MAPK14 894/4885TDP1 4605/4885ALDH1A1 2869/4885 |
| US-20150011555-A1 | Salts of an IP Receptor Agonist | INSR, GPR27, GIPR | MAPK14 3194/4885TDP1 4543/4885ALDH1A1 2795/4885 |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | PTGIR, ACVR1, PTGFR | MAPK14 894/4885TDP1 4605/4885ALDH1A1 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.